Table 1.
Relative risk of severe infectious events according to tumor types, VEGFR-TKIs, and phases of trials
| Groups | Studies, n | Severe infectious events, n/total, n
|
RR (95% CI) | P-value | Numbers needed to harm | P-value for group difference | |
|---|---|---|---|---|---|---|---|
| VEGFR-TKIs | Control | ||||||
| Tumor types | |||||||
| NSCLC | 10 | 362/4,891 | 210/4,597 | 1.65 (1.39–1.96) | <0.001 | 35 | 0.85 |
| CRC | 3 | 43/1,389 | 19/995 | 1.99 (1.19–3.33) | 0.009 | 84 | |
| Thyroid cancer | 3 | 6/510 | 1/381 | 3.57 (0.78–16.33) | 0.10 | 109 | |
| HCC | 2 | 2/293 | 4/302 | 0.52 (0.10–2.65) | 0.44 | 155 | |
| Others | 9 | 71/1,854 | 40/1,492 | 1.73 (1.17–2.56) | 0.006 | 87 | |
| VEGFR-TKIs | |||||||
| Vandetanib | 7 | 111/2,387 | 69/1,936 | 1.25 (0.92–1.70) | 0.16 | 92 | 0.48 |
| Sorafenib | 7 | 87/1,467 | 43/1,497 | 2.11 (1.48–3.00) | <0.001 | 33 | |
| Sunitinib | 5 | 52/1,732 | 23/1,435 | 2.18 (1.35–3.53) | 0.001 | 72 | |
| Cediranib | 2 | 14/653 | 8/511 | 1.56 (0.66–3.65) | 0.31 | 174 | |
| Regorafenib | 2 | 9/637 | 2/319 | 1.99 (0.57–7.02) | 0.28 | 128 | |
| Others | 4 | 211/2,061 | 129/2,069 | 1.62 (1.32–2.00) | <0.001 | 25 | |
| Phases of trials | |||||||
| Phase II | 4 | 22/680 | 15/424 | 1.21 (0.60–2.44) | 0.60 | 336 | 0.29 |
| Phase III | 23 | 462/8,257 | 259/7,343 | 1.71 (1.47–1.99) | <0.001 | 48 | |
| Overall | 27 | 484/8,937 | 274/7,767 | 1.69 (1.45–1.96) | <0.001 | 53 | NA |
Abbreviations: VEGFR-TKIs, vascular endothelial growth factor receptor tyrosine kinase inhibitors; RR, relative risk; CI, confidence interval; NSCLC, non-small-cell lung cancer; CRC, colorectal cancer; HCC, hepatocellular carcinoma; NA, not available.